Weird Science: 4 Healthcare And Medical Device Companies Developing Futuristic Technologies In 2016
ACCESSWIRE
WINDSOR, ON / ACCESSWIRE / January 29, 2016 / The Wealthy Biotech Trader (or "WBT"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, has developed a list of stocks skirting the boundaries of reality which could make a big contribution to healthcare innovation in 2016 and beyond.
We will get into the details below, but first, here is our list:
1) Endonovo Therapeutics, Inc. (ENDV) 2) Second Sight Medical Products, Inc. (EYES) 3) Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) 4) Sangamo BioSciences Inc. (SGMO)
First and foremost Endonovo Therapeutics, Inc. (ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine to help those in need. This biotech company has clearly created a technology way ahead of its time set to benefit those in need. In need, meaning, potentially any individual with liver failure, which affects tens of thousands of individuals worldwide. The only potential cure prior to Endonovo's medical device (pending FDA approval) was a liver transplant, which most would wait on a lengthy list and possibly die before anything could even be done. With technology like this, way ahead of its time, it's a wonder that large Investors and big pharma have not jumped all over this company.
Endonovo's Immunotronic technology was originally developed at NASA to treat injury and diseases astronauts may encounter during long-term missions. However, the non-implantable bioelectronic device ENDV has for potentially treating/preventing vital organ failure through the reduction of inflammation and the promotion of regeneration has been designed to be completely safe and non-invasive. Based on approval for safety and effectiveness, this could be a potential paradigm shift for all those suffering from failing organs, to be first shown on the human liver.
Endonovo's other device, the Cytotronic platform, provides for a method of expanding and enhancing cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for cell therapies which the company intends to utilize in the treatment of graft versus host disease.
The company has developed a different type of science. A science some may call futuristic because of its healing capabilities. Only a few years ago, the only treatment for liver disease was a transplant, now ENDV has stepped into the picture and could change this world as we know it.
Second Sight Medical Products, Inc. (EYES) is truly a remarkable company with its mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Who would have ever thought the blind could have a chance to see again? Not many. This type of technology is beyond unique-- Some may even call it futuristic.
EYES's technology is not for all blind people, but for the individuals who lost their vision due to retinitis pigmentosa (RP) which severely damages the photoreceptors in our eyes. Second Sight has already developed and has started manufacturing the Argus(R) II Retinal Prosthesis System. Enrollment is underway in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration as a second indication for treatment. Second Sight is also developing the Orion(TM) I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. Science such as this is mind blowing, and this company is doing everything in its powers to help individuals see again. Most who go blind, for whatever the reason, tend to lose hope, but with companies such as EYES around, we believe hope should not be lost.
Corindus Vascular Robotics Inc. (NYSE MKT:CVRS) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs), a non-surgical procedure that uses a catheter (a thin flexible tube) to place a small structure called a stent to open up blood vessels in the heart that have been narrowed by plaque buildup.
The company's CorPath System is the first system that is actually FDA-cleared. This medical device called a CorPath system is the first of its kind that offers interventional cardiologists PCI, a procedure control from a radiation protective interventional cockpit. The occupational hazards in the cath lab are extremely serious due to radiation. As the PCI procedures became more complex and longer, so did radiation exposure and time in heavy led gear. However, with science on their side, Corindus developed the much talked about CorPath system to bring robotic precision to interventional cardiology. Doing all this while enabling a safer work environment for the cath lab team. The benefits of the CorPath Robotic-Assisted PCI are tremendous in results: First of all, there is a 95% reduction in radiation exposure alone for the primary operator. Also, they are now able to perform procedures much more safely and comfortably, while being seated without all the heavy radiation gear. The list of positives goes on and on and the fact that it's FDA-cleared should be a clear sign to investors all over that potential revenue growth could accelerate.
Sangamo BioSciences (SGMO) Inc. is focused on engineering genetic cures for monogenic and infectious diseases by deploying its novel DNA-binding protein technology. Gene-Editing isn't simple; it requires the smartest of individuals to be in the field working countless hours to solve the codes of the complex human body to "edit out/ edit in" certain problem/ solution genes linked to disease.
This scientific gene-editing company has a pipeline of therapies it is developing with no clear (publically traded) competitors in sight. With the much anticipated IPO of Editas, a gene editing biotech with big Investor names behind it, 2016 may see a lot of the hot/ momentum money flow into this niche of biotech.
They are already in clinic with phase 2 trials for their HIV/ AIDS (T-Cell), Phase 1 of their HIV / AIDS (Stem Cell), Phase 1 of Hemophilia B, and numerous of other diseases that they are working on. Quite the pipeline. This companys strategy is to develop their ZFP technology through research, preclinical and early stage clinical testing. After proof of concept and early positive clinical data, they will look to partner or license a part of their technology to larger players in the biotech arena.
Based on the predicted money-flow into this space by the financial pundits and Wall Street as a whole, this name should at the very least be watch-listed starting from the time Editas prices their IPO (symbol to be EDIT), as strong trading for them out of the gate may re-ignite the whole biotech complex and supercharge those in the gene editing space.
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Text Message Alerts, Twitter and Facebook.
This report/release/profile is a commercial advertisement and is for general information and entertainment purposes only. We are engaged in the business of marketing and advertising companies formonetary compensationunless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.
The Wealthy Biotech Trader's controlling parent company has been compensated $150,000 by Endonovo Therapeutics, Inc. in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.
